Solid Biosciences (SLDB) Non-Current Deffered Revenue (2017 - 2021)
Quarterly results put Non-Current Deffered Revenue at $2.3 million for Q3 2021, changed N/A from a year ago — trailing twelve months through Sep 2021 was $2.3 million (changed N/A YoY), and the annual figure for FY2020 was $10.4 million, changed.
Solid Biosciences has reported Non-Current Deffered Revenue over the past 3 years, most recently at $2.3 million for Q3 2021.
- Non-Current Deffered Revenue reached $2.3 million in Q3 2021 per SLDB's latest filing, down from $4.3 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $10.4 million in Q4 2020 and bottomed at $2.3 million in Q3 2021.
- Median Non-Current Deffered Revenue over the past 3 years was $4.3 million (2021), compared with a mean of $5.4 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 225.10 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 2.26 Mn |
| Jun 30, 2021 | 4.31 Mn |
| Mar 31, 2021 | 7.00 Mn |
| Dec 31, 2020 | 10.36 Mn |
| Dec 31, 2017 | 3.11 Mn |